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A STUDY OF SERUM MAGNESIUM LEVEL IN PATIENTS WITH 
TYPE 2 DIABETES MELLITUS 
ABSTRACT: 
 Type 2 diabetes mellitus constitutes around 80 to 95 % of adult onset 
diabetes. Hypomagnesemia is associated with type 2 diabetes but a significant 
proportion of population suffering from this metabolic disorder is not aware 
about it. This study was conducted in the General Medicine OPD, Government 
Rajaji Hospital, Madurai from April 2014 to September 2014 to measure the 
serum magnesium level in type 2 diabetes patients. A total of 200 subjects were 
selected, of which 100 were type 2 diabetic patients and 100 were age and sex 
matched healthy non-diabetic controls. Mean serum magnesium level was 
significantly (p<0.001) lower in type 2 diabetic patients when compared to that 
of non-diabetic healthy controls. Also, mean serum magnesium level is 
significantly lower in uncontrolled diabetic patients when compared to that of 
controlled diabetics. 
KEY WORDS: 
 Type 2 Diabetes, Hypomagnesemia, serum magnesium 
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INTRODUCTION 
Diabetes mellitus is a syndrome of impaired carbohydrate, protein 
and fat metabolism due to lack of secretion of insulin. Although diabetic 
patients have a normal lifestyle, its late complications will result in 
reduced life expectancy and major health cost. These include 
macrovascular diseases which leads to increase in prevalence of 
peripheral vascular disease, coronary artery disease, stroke and 
microvascular damage which leads to nephropathy, retinopathy and 
neuropathy. 
Magnesium is present in higher concentration within the cell and it 
is the second most abundant cation next to potassium. It plays an 
important role in manipulating important biological pyrophosphate 
compounds. The disturbance in magnesium level i.e., hypomagnesemia 
has been reported to be occur in diabetic patients.  
Although diabetes can induce hypomagnesemia, magnesium 
deficiency has also been proposed as a risk factor for diabetes. Animal 
studies have shown that magnesium deficiency has a negative effect on 
post receptor signalling of insulin. Some short term metabolic studies 
suggested that magnesium supplementation has a beneficial effect on 
insulin action and glucose metabolism. 
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Persistent hypomagnesemia leads to raised glucose level, insulin 
resistance and the degree of magnesium depletion positively correlates 
with serum glucose concentration and degree of glycosuria. 
The cause of hypomagnesemia was attributed to (1).Osmotic renal 
loss from glycosuria, (2). Decreased intestinal absorption of magnesium. 
Recently a specific tubular magnesium defect in patients with diabetes 
has been postulated. Hypermagnesuria results specifically from reduction 
in tubular absorption of magnesium. 
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AIMS AND OBJECTIVES 
 
1. To compare the level of serum magnesium in type 2 diabetes 
patients and non diabetic healthy controls. 
2.  To study the level of serum magnesium in controlled and 
uncontrolled diabetics. 
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REVIEW OF LITERATURE 
MAGNESIUM: 
Magnesium is the eighth most common element in earth’s crust. 
Oceans and rivers are the most plentiful source of biologically available 
magnesium. Magnesium is easily dissolved in water and it is more soluble 
than calcium salts. Magnesium is the central ion of chlorophyll in plants. 
Magnesium is the fourth most abundant cation in vertebrate animals and it 
is the second most intracellular cation next to potassium
1
. Magnesium 
salts are used traditionally as antacid and laxatives in the form of 
magnesium hydroxide, magnesium citrate, magnesium sulphate and 
magnesium chloride. 
CHEMICAL CHARACTERISTICS: 
Symbol: Mg 
Element category: alkaline earth metal. 
Atomic number: 12 
Valency: 2 
Crystal structure: hexagonal 
Atomic radius: 0.65 angstrom unit 
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Atomic weight: 24.305 g/mol 
Specific gravity: 1.738 
No. of hydration cells: 2 layers 
Melting point: 648.8 
0
C 
Boiling point: 1090 
0
C 
Magnesium cannot be passed through narrow channels in 
biological membranes unlike calcium because it cannot be easily stripped 
of its hydration shell. Proteins which transport magnesium have to 
recognize the large hydrated cation and strip of its hydration shell and 
deliver the dehydrated ion to transmembrane transport pathway through 
the membrane. 
PHYSIOLOGICAL ROLE OF MAGNESIUM IN THE BODY: 
Most animals contain approximately 0.4 g magnesium / kg. Human 
body contains around 20mmol/kg of magnesium in fat free tissue. 
DISTRIBUTION: 
  Ninety nine percent of total body magnesium is present in muscles, 
bone and non muscular soft tissues
2
. Fifty to sixty percent of magnesium 
resides as the hydroxyapatite mineral component of bone. As age 
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increases, magnesium content in bone decreases. During acute changes in 
serum magnesium concentration, bone provides a large exchangeable 
pool. One-third of skeletal magnesium is exchangeable and serves as the 
reservoir to maintain physiological extracellular magnesium. Intracellular 
magnesium concentrations range from 5 to 20mmol/L, of which 1 to 5 
percent is in ionised form and the remainder is bound to proteins, 
adenosine triphosphate (ATP) and negatively charged molecules. Extra 
cellular magnesium is about 1% of total body magnesium and it is found 
mainly in serum and red blood cells (RBCs).  
Extra cellular magnesium exist in three fractions – ionised/free, 
protein bound and complexed with anions like phosphate, bicarbonate and 
sulphate or citrate
3
. Out of these three fractions, ionised magnesium has 
the greatest biological activity. 
  Magnesium acts as a cofactor in more than 300 enzyme regulated 
reactions, particularly reactions forming and using ATP. There is a direct 
effect on sodium (Na
+
), potassium (K
+
) and calcium (Ca
2+
) channels. 
Magnesium acts as an essential cofactor for enzymes concerned with cell 
respiration and glycolysis. Activity of Sodium-Potassium ATP-ase 
depends on magnesium.  
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Magnesium can affect enzyme activity by binding in the active site 
and causing conformational changes during catalytic process and also by 
promoting aggregation of multi enzyme complexes. Magnesium also 
affects permeability characteristics and electrical properties of cell 
membrane. Reduced extracellular magnesium concentration increases 
membrane excitability in tissues.  
Magnesium also acts to maintain a low resting concentration of 
intracellular calcium. Magnesium competes with calcium for membrane 
binding sites and stimulates calcium sequestration by sarcoplasmic 
reticulum. ATP metabolism, normal neurological function, muscle 
contraction and relaxation and release of neurotransmitters are 
magnesium dependent.  
Magnesium also regulates vascular tone, bone formation and heart 
rhythm. Magnesium has a role in insulin secretion. Magnesium is 
considered as a natural ‘calcium antagonist ’. Magnesium inhibits calcium 
induced cell death and antagonizes calcium overload triggered apoptosis. 
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FUNCTIONS OF MAGNESIUM: 
 The various functions of magnesium are as follows: 
1. ENZYME FUNCTION: 
  (A)Enzyme substrate:  
 Hexokinase 
Protein kinase 
Creatine kinase 
Sodium potassium ATPase 
Calcium ATPase 
Adenylate cyclase 
Guanylate cyclase 
(B) DIRECT ENZYME ACTIVATION: 
  Phosphofructokinase 
  Creatine kinase 
  Adenylate cyclase 
  5-phosphoribosyl-pyrophosphate synthetase 
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  Sodium potassium ATPase. 
2. MEMBRANE FUNCTION: 
  Cell adhesion 
  Transmembrane electrolyte flux 
3. CALCIUM ANTAGONIST: 
  Membrane contraction/relaxation 
  Neurotransmitter release 
  Action potential conduction in nodal tissue 
4. STRUCTURAL FUNCTION: 
  Proteins 
  Nucleic acid 
  Polyribosomes 
  Mitochondria 
  Multiple enzyme complexes 
REGULATION OF MAGNESIUM INFLUX AND EFFLUX: 
Exchange of intracellular and extracellular magnesium in 
mammalian myocardium, fat tissue, renal parenchyma, brain tissue, 
10 
 
skeletal muscle and lymphocyte occurs in different rates.  In man, 
equilibrium for magnesium is reached very slowly in most tissue 
compartments. 
MAGNESIUM CONSUMPTION: 
Humans have to consume magnesium regularly to prevent its 
deficiency. Recommendations in literature suggests lower daily minimum 
magnesium intake of 350mg for men, 280 to 300mg for women, 355mg 
during pregnancy and lactation.  
SOURCES OF MAGNESIUM: 
Magnesium is found abundant in nature. Magnesium content in 
food varies widely.  
It is present in green leafy vegetables, chlorophyll, cocoa 
derivatives, nuts, wheat, seafood and meat.  
Legumes, fish and fruits have intermediate magnesium 
concentration.  
Dairy products have low magnesium concentrations. 
 All processed foods have low concentration of magnesium than 
unrefined food products. 
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RECOMMENDED DIETARY ALLOWANCE OF MAGNESIUM: 
 Recommended dietary allowances(RDA) 
Age Magnesium(mg/day) 
Infants 0-5 months 
5 months-1 year 
40 
60 
Children 1-3 years 
4-6 years 
7-10 years 
80 
120 
170 
Males 11-14 years 
15-18 years 
19-22 years 
23-50 years 
Above 50 years 
270 
400 
350 
350 
350 
Females 11-14 years 
15-18 years 
19-22 years 
23-50 years 
Above 50 years 
280 
300 
280 
280 
280 
Pregnancy 
Lactating women 
 320 
355 
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MAGNESIUM ABSORPTION AND EXCRETION: 
Magnesium homeostasis comprises three systems- kidney, bone 
and small intestine. 
 Magnesium is absorbed in the small intestine and gets stored in the 
bone and excess of it gets excreted in urine and faeces.  
Kidneys mainly regulate serum magnesium. About 2400 mg of 
magnesium passes through kidneys daily of which 5 percent (120 mg) is 
excreted through urine. Major site of magnesium homeostasis in kidney is 
loop of Henle in which 65 percent of magnesium gets reabsorbed
4
.  
Magnesium is mainly absorbed in the small intestine by a passive 
paracellular mechanism. A minor fraction of magnesium is transported 
through transcellular transporter TRPM (Transient Receptor Potential 
channel Melastatin member) 6 and TRPM 7. Around 24 to 76% of 
magnesium is absorbed from the gut and the rest is eliminated in the 
faeces. Intestinal absorption of magnesium does not depend on 
magnesium intake but it is dependent on magnesium status. When 
magnesium level is low, intestinal absorption of magnesium gets 
increased and vice versa. 
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LABORATORY ASSESSMENT OF MAGNESIUM: 
Serum /Plasma Magnesium Concentration: 
It provides an approximate guide to the presence or absence of 
magnesium deficiency
5
. Hypomagnesemia reliably indicates magnesium 
deficiency.  
Magnesium concentration in muscle: 
Muscle contains about 27% of total magnesium. Needle biopsy is 
used to find concentration of magnesium in muscle but it is an invasive 
procedure and it requires special skills. 
Mononucleated white cell magnesium concentration: 
It is the possible index for intracellular magnesium
6
. In humans, it 
does not correlate with erythrocyte or serum concentration. It is the better 
indicator for cardiac arrhythmia associated with magnesium deficiency. 
Magnesium retention test (loading test): 
Oral/ IV magnesium loading tests are described and it is used for 
diagnostic purpose. In normal individuals, all injected magnesium is 
excreted in urine within 24 to 48 hours after administration. If the 
retention of infused magnesium is less than 30%, it suggests magnesium 
deficiency unlikely. Precautions to be taken before performing this test - 
14 
 
patient should have normal kidneys, should not have taken any 
medication affecting magnesium excretion in kidney and should not have 
cardiac conduction disturbances. 
METHODS USED TO MEASURE MAGNESIUM: 
Serum magnesium is measured by various techniques like titration, 
precipitation, photometry, fluorometry and flame emission spectroscopy. 
In most of the techniques, precipitation of magnesium by 8-hydroxy 
quinolone is the basis for magnesium measurement. Now, enzymatic 
method is used with hexokinase or other enzymes that utilise Mg-ATP as 
the substrate
7
. Today most commonly used technique in many 
laboratories is photometric method
8
. 
Photometric method: 
A number of metallochromatic dyes / indicators are used and it 
changes colours by selectively binding with magnesium.  
Calmagite – a metallochromatic indicator forms coloured complex 
when it binds with magnesium in alkaline solution and it is measured at 
530 to 550 nm
9
. To prevent interference by calcium, specific calcium 
chelating agent EGTA [Ethylene Glycol- O,O- bis( 2- aminoethyl) N,N 
Tetra Acetic acid] is added. To avoid the heavy metal complex formation 
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potassium cyanide (KCN) is added. Polyvinylpyrrolidone and surfactant 
are also included to reduce the interference from lipemia and protein
10
. 
Methylthymol blue – forms blue complex when binds with 
magnesium and it is measured at 600nm. To prevent interference by 
calcium, EGTA is added.  
Magon or xylidyl blue binds with magnesium in alkaline medium 
and forms red complex
11
. Protein and calcium interference is prevented 
respectively by dimethyl sulfoxide and EGTA respectively
12
. 
Specimen: 
Serum is the preferred specimen. Anticoagulants like oxalate, 
EDTA and citrate should not be used because they form complexes by 
binding with magnesium. When serum is kept at 4
o
C, magnesium is stable 
for days and when frozen, it is stable for months. Serum/plasma should be 
separated from red blood cells or clot as early as possible to avoid false 
increase in magnesium levels due to cell leakage.  
Reference value: 
Reference interval for serum magnesium is 0.70 to 0.99 mmol/L 
(1.3 to 2.5 mEq/L).  
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CLINICAL SIGNIFICANCE: 
HYPERMAGNESEMIA: 
Under normal physiological conditions, magnesium is excreted in 
urine. Hypermagnesemia occurs when renal function is impaired or when 
there is excess of magnesium load. 
Causes
13
: 
1. Renal failure 
2. Magnesium infusion 
3. Primary hyperparathyroidism 
4. Diabetic ketoacidosis 
5. Adrenal insufficiency 
6. Tumour lysis syndrome 
7. Milk alkali syndrome 
Clinical features: 
Symptoms are ranging from asymptomatic to life threatening 
events.   
Magnesium concentration of 4 to 6 mEq/L leads to nausea, 
lethargy, headache and sluggish deep tendon reflexes.  
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Magnesium concentration of 6 to 10 mEq/L leads to hypocalcemia, 
somnolence, absent reflex and hypotension.  
Magnesium concentration more than 10 mEq/L leads to complete 
heart block, muscle paralysis, respiratory and cardiac arrest.  
Management: 
It can be prevented by avoiding magnesium load in patients with 
impaired renal function tests. Stopping magnesium supplements with 
normal renal function will allow restoration of magnesium to normal 
levels. I.V Calcium gluconate can be used as magnesium antagonist. In 
severe life threatening hypermagnesemia and in patients with renal failure 
hemodialysis is indicated. 
HYPOMAGNESEMIA: 
Hypomagnesemia is common in ICU settings with nutrition, 
diuretics, etc. In the presence of hypomagnesemia, renal excretion of 
magnesium is decreased. Hypomagnesemia also occurs in gastrointestinal 
and renal losses. It is often associated with hypokalemia, hypocalcemia 
and metabolic acidosis.  
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Causes: 
1. Chronic diarrhoea 
2.  Steatorrhoea 
3.  Malabsorption syndrome 
4.  Small bowel resection 
5.  Alcoholics 
6.  Acute pancreatitis 
7.  Diuretics – both loop and thiazides 
8.  Bartter and Gitelman syndrome 
9.  Primary aldosteronism 
10. Hypercalcemia 
11. Drugs- Aminoglycosides, proton pump inhibitors, cisplatin 
12. Hungry bone syndrome following parathyroidectomy 
13. Transplant kidney 
14. Diabetes mellitus 
15. Pregnancy 
16. Respiratory alkalosis 
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Clinical features: 
Neuromuscular –  Weakness 
   Tremor 
   Muscle fasciculation 
   Dysphagia 
   Positive chvostek’s sign 
   Positive trousseau’s sign 
Cardiac –   Arrhythmias 
   Hypertension 
   Tachycardia 
CNS –  Depression 
    Agitation 
   Psychosis 
   Nystagmus 
   Seizures 
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Metabolic –  Hypokalemia 
   Hypocalcemia 
ECG changes – Widening of QRS complex 
   Flattening of T waves 
   QTc prolongation 
   ST segment depression 
   Prolonged PR interval 
   Ventricular arrhythmia 
Management: 
Correct the underlying cause of hypomagnesemia. Replacement of 
magnesium by oral route in asymptomatic patients and those with mild 
deficiency by supplementing sustained release formulations. I.V 
magnesium is required in patients with tetany and ventricular arrhythmia. 
MAGNESIUM DEFICIENCY IN DIABETES: 
Magnesium ion has an important fundamental role in metabolism 
of carbohydrate and particularly in the action of insulin
14
. Magnesium 
acts as a cofactor of various enzymes involved in carbohydrate oxidation.  
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Magnesium is involved in multiple steps in insulin secretion, 
insulin binding and activity. It is a cofactor for adenylate cyclase and 
ATPase. Recently it has been proposed that magnesium plays a novel 
factor in pathogenesis of complications in diabetes. Relation between 
magnesium and carbohydrate intolerance, insulin resistance, accelerated 
atherosclerosis, hypertension, dyslipidemia has been observed. 
 It is important to recognize the symptoms and signs of diabetes 
associated magnesium deficiency because its deficiency occurs long 
before its reflection in serum values. It has been suggested that there is 
prevalence of 25 to 39% of magnesium deficiency associated with 
diabetes mellitus.  
Hypomagnesemia in diabetes indicates secondary magnesium 
deficiency. Mechanism for magnesium deficiency in diabetes mellitus is 
not exactly known. It has been proposed that osmotic diuresis is 
responsible for magnesium loss. Glycosuria, which accompanies the 
diabetic state, impairs the magnesium reabsorption from renal tubules.  
Magnesium is principally reabsorbed in proximal tubule (30%), ascending 
loop of Henle (65%) with minimal (1 to 5%) reabsorption in distal 
convoluted tubule. Glucose is a crucial part in maintaining cellular ion 
homeostasis, increasing intracellular calcium level and decreasing 
intracellular magnesium level. Influence of magnesium on ATPase 
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activity in cell membrane and consequently on sodium, potassium and 
calcium metabolism play a role in diabetic complications. Sodium 
potassium ATPase which is necessary to maintain intracellular potassium 
is a magnesium dependent enzyme. Impaired enzymatic activity plays a 
role in pathogenesis of diabetic polyneuropathy.  
Possible causes of hypomagnesemia in diabetes: 
1. Reduced renal reabsorption 
2. Enhanced filtered load 
3. Enhanced gastrointestinal loss 
4. Decreased intake 
MAGNESIUM DEFICIENCY AND OXIDATIVE STRESS: 
Diabetes is a state of increased free radical activity
15
. It is 
associated with increased prevalence of atherosclerotic disease and 
cardiovascular morbidity and mortality. Lipid peroxidation is a 
consequence of free radical activity which plays an important role in 
atherosclerosis, aging and late diabetic complications. Glutathione, which 
is thiol containing tripeptide, is present in plasma in reduced state. It has 
antioxidant properties. Magnesium acts as a cofactor for enzymatic 
reaction of glutathione synthesis. 
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MAGNESIUM DEFICIENCY AND CARDIOVASCULAR 
DISEASE: 
Magnesium has some relationship with pathogenesis of 
atherosclerosis and hypertension and diabetes. Several studies have 
shown that there is magnesium deficiency in hypertensive animals and 
there is inverse relationship between diastolic blood pressure and 
intracellular magnesium ion
16
. Some studies have shown that at the onset 
of pathogenesis there is alteration in ionic metabolism in which there is 
increase in intracellular calcium and decrease in intracellular magnesium.  
The pathophysiological disorders due to magnesium deficiency in 
cardiovascular system are vasospasm, free radical generation, increase in 
vasoconstrictor activity, increase in intracellular calcium in smooth 
muscle and cardiac muscle, formation of pro-inflammatory agents. These 
contribute to blood pressure modification during magnesium deficiency. 
Magnesium depletion directly cause vasoconstriction and hypertension 
and predispose to cardiac arrhythmias and sudden death. Magnesium 
deficiency is also associated with hyperlipidemia
17
.  
Thus Magnesium deficiency in diabetes gains importance as it 
increases the complications of diabetes and other associated systemic 
illnesses. 
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DIABETES MELLITUS: 
Diabetes mellitus is a metabolic disorder of multiple etiology, 
characterised by chronic hyperglycemia with disturbances of 
carbohydrate, protein and fat metabolism resulting from defects of insulin 
secretion, insulin action or both. Sustained exposure to these 
abnormalities is accompanied by microvascular complications 
(retinopathy, nephropathy and neuropathy) as well as macrovascular 
complications (stroke, myocardial infarction and peripheral arterial 
vascular disease). 
PHYSIOLOGICAL ANATOMY OF PANCREAS: 
 It is composed of two major tissues – acini and islets of 
Langerhans. Acini secrete digestive juices into the duodenum. Islets of 
Langerhans secrete insulin and glucagon directly into the blood.  
Human pancreas contains 1 to 2 million islets, each islet is about 
0.3 mm in diameter. It is organised around the blood vessels (small 
capillaries) so that it secrete hormones directly into the blood. 
There are three major cell types present in islets 
o Alpha cell 
o Beta cell 
o Delta cell 
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Each cell is distinguished from one another by their staining and 
morphological characteristics. 
 Nearly 60% of islets are made up of beta cells. It lies in middle of 
the islet. It secretes mainly two hormones – insulin and amylin. Amylin 
secretes in parallel with insulin secretion and its role is unclear. 
 Nearly 25% of islets contain alpha cells. It secretes glucagon. 
 Nearly 10% of islets contain delta cells. It secretes somatostatin. 
 There is another type of cell which is present in small number – PP 
cell, which secretes pancreatic polypeptide. 
 There is close interrelationship exists between these cell types 
 Amylin inhibits insulin secretion 
 Insulin inhibits glucagon secretion 
 Somatostatin inhibits both insulin and glucagon secretion. 
 
INSULIN AND ITS METABOLIC EFFECTS: 
Insulin secretion is associated with energy abundance. When food 
contains excess carbohydrate, it stimulates insulin secretion in large 
amount. In turn, it plays important role in storing these excess energy in 
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the form of glycogen in liver and muscles and by converting to fats and 
gets deposited in adipose tissue
18
. It also promotes aminoacid uptake by 
the cells. 
INSULIN CHEMISTRY: 
Aminoacid chain: 2 (each connected by disulfide linkage) 
Molecular weight: 5808 
When these 2 aminoacid chains are split, it loses its functional activity. 
SYNTHESIS OF INSULIN: 
First it begins with insulin RNA translation that occurs in 
ribosomes attached to ER( Endoplasmic Reticulum). It forms ‘insulin 
prohormone’ (molecular weight: 11,500). Then it is cleaved in ER to form 
‘proinsulin’. Proinsulin has no insulin activity. Then cleavage occurs in 
golgi apparatus to form insulin and peptide fragments.  
 When insulin is secreted into the blood stream, it is mostly in 
unbound form. So it is rapidly cleared from the blood within 10 mins. It is 
degraded by the ‘insulinase enzyme’ which is secreted from the liver. So 
its plasma half life is about 6 minutes. 
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INSULIN RECEPTOR: 
 It is an enzyme linked receptor. It contains four subunits- 2 alpha 
and 2 beta units which are linked by disulfide bond.  
2 alpha subunits- lie entirely outside the cell membrane 
2 beta subunits- penetrate through membrane and protrudes into 
cytoplasm. Autophosphorylation occurs in beta subunits and activate 
tyrosine kinase. 
EFFECTS OF INSULIN STIMULATION: 
1. Within seconds, it increases the uptake of glucose within the 
muscle cell and adipose tissue by increasing glucose transport by 
increase in translocation of intracellular vesicles to the cell 
membrane. 
2. It makes cell membrane more permeable to transport potassium 
ions, amino acid and phosphate ions. 
3. Within minutes, it changes the activity of many intracellular 
metabolic enzymes. 
4. Much slower effect occurs in hours/days - formation of new 
proteins by changing the rates of translation of mRNA (messenger 
RNA) at ribosomes. 
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EFFECT OF INSULIN ON METABOLISM OF 
CARBOHYDRATE: 
 Most of the day, muscle depends mainly on fat for its energy source 
and not glucose. Muscle cell resting membrane is less permeable to 
glucose. When insulin concentration increases, it makes cell membrane 
more permeable to glucose
18
. Conditions in which the muscle utilises 
glucose are (a) after moderate/heavy exercise (b) few hours after the 
meal.  
 If the muscle is not exercising after the meal, yet large amount of 
glucose is transported into muscle cells – then this excess glucose is 
converted into glycogen and stored.  
 One of the most important effects of insulin is the storage of 
glycogen in liver. Mechanisms by which insulin cause uptake and storage 
of glucose in liver includes 
 It inactivates liver phosphorylase thereby preventing breakdown of 
glycogen. 
 It activates glucokinase enzyme thereby increasing uptake of 
glucose into liver cells and it gets phosphorylated. 
 It promotes glycogen synthase enzyme and it helps in 
monosaccharide unit polymerisation to form glycogen. 
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Thus, the liver removes excess glucose from the blood after the meals and 
once the blood glucose falls in between the meals, the stored glucose is 
released back into the blood. 
 Insulin promotes conversion of excess glucose in the liver into fatty 
acids and it is subsequently stored as triglycerides in VLDL (Very Low 
Density Lipoprotein). 
 Insulin also decreases the activity and quantity of liver enzymes 
that is required for gluconeogenesis and inhibits it. 
EFFECTS OF INSULIN IN FAT METABOLISM: 
Effects of insulin in long term in fat metabolism are equally 
important. Long term effect of lack of insulin causes atherosclerosis, 
stroke, MI and other vascular disorders. 
Factors that lead to increased fatty acid synthesis and storage are 
  Once the glycogen concentration reaches 5 to 6% in the liver, 
glycogen synthesis gets stopped. Then this excess glucose is 
converted to fatty acid by activating glycolytic pathway. In 
glycolytic pathway, pyruvate is produced. It is converted into  
acetyl CoA (acetyl coenzyme A),that acts as a substrate for  
fatty acid synthesis. 
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 In Kreb cycle (citric acid cycle), glucose is converted into 
citrate and isocitrate, there by activating acetyl CoA 
carboxylase, fatty acids are synthesised. 
 Insulin activates lipoprotein lipase enzyme in the capillary wall 
of adipose tissue. There triglycerides are broken down into FFA 
(free fatty acid) and gets absorbed into adipose tissue. Within 
adipose tissue these FFA are again converted back to 
triglycerides and stored. 
 Insulin inhibits hormone- sensitive lipase action, thereby 
preventing breakdown of triglycerides in the adipose tissue. 
EFFECTS OF INSULIN IN PROTEIN METABOLISM AND 
GROWTH: 
 Insulin stimulates the uptake of many aminoacids like valine, 
leucine, isoleucine, tyrosine and phenylalanine. 
 Insulin acts as  ‘on and off’ mechanism in ribosomes. It helps in 
formation of protein by translation of mRNA. 
 It inhibits protein catabolism, thereby preventing release of amino 
acid from the cell. 
 Insulin and growth hormone acts synergistically to promote 
growth.  
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This diagram represents the actions of insulin. 
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MECHANISM OF INSULIN SECRETION: 
Glucose enters into beta cell by GLUT 2 transporter 
 
Glucose is phosphorylated into glucose 6 phosphate by glucokinase( rate 
limiting step in beta cell)
18 
 
Glucose 6 phosphate is oxidised to form ATP (adenosine tri phosphate) 
 
Inhibition of ATP- sensitive potassium channel 
 
Depolarisation of membrane and opening of voltage gated calcium 
channel 
 
Fusion of insulin containing vesicles with the cell membrane 
 
Secretion of insulin by exocytosis 
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This picture represents the secretion of insulin in response to glucose 
stimulation. 
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FACTORS MODULATING INSULIN SECRETION: 
There are various gut hormones which modulate the secretion of 
insulin. They are GLP-1(glucagon like peptide), GIP 1 and 2 (glucose 
dependent insulinotropic peptide), cholecystokinin , secretin , vasoactive 
intestinal polypeptide, and gastrin.  
FACTORS THAT INCREASE INSULIN SECRETION: 
 Increased blood glucose 
 Increased free fatty acid in blood 
 Increased amino acid in blood 
 Glucagon, growth hormone 
 Cortisol 
 Acetyl choline 
 Parasympathetic stimulation 
 Insulin resistance 
 Obesity 
 Gastrointestinal hormones like gastrin, secretin 
 Sulfonylurea drugs 
 Beta adrenergic stimulation 
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FACTORS THAT DECREASE INSULIN SECRETION: 
 Decreased blood glucose 
 Somatostatin 
 Alpha adrenergic activity 
 Leptins 
 Fasting  
CONTROL OF INSULIN SECRETION: 
 Rate of insulin secretion rises rapidly when the blood glucose 
concentration increases above 100mg/100ml of blood. 
 When blood glucose concentration reaches 400 to 600 mg/100ml, 
insulin secretion reaches a peak of 10 to 25 times the basal level. 
 When the blood glucose comes back to fasting level, insulin 
secretion gets turn off within 3 to 5 minutes. This response of insulin to 
an elevated blood glucose level provides an extremely important feedback 
mechanism for regulating blood glucose concentration. 
ETIOLOGICAL CLASSSIFICATION OF DIABETES MELLITUS: 
  In 1997, ADA Expert committee on the Diagnosis and 
Classification of diabetes mellitus recommended modifications in the 
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classification system which was developed by National Diabetes Data 
Group (NDDG) and Diabetes mellitus is classified on the basis of 
pathogenesis,( as opposed to earlier criteria such as age of onset or type of 
therapy), into two broad categories as type 1 and type 2
19
 .  
It also includes eight other specific types of diabetes. 
1. Genetic defects of beta cell function 
2.  Genetic function in insulin action 
3. Diseases of exocrine pancreas 
4. Endocrinopathies 
5. Drug/chemical induced 
6. Infections 
7. Uncommon forms of immune mediated diabetes 
8. Other genetic syndromes associated with diabetes 
TYPE 1 DIABETES: 
Type 1 diabetes mellitus is the result of complete or near total 
insulin deficiency due to cell-mediated autoimmune pancreatic β-cell 
destruction and they are prone to develop ketoacidosis.   
Aetiology is unknown. It may be immune mediated or idiopathic. 
This is usually diagnosed in children and young adults but may be 
diagnosed in adults also. Markers of this process include 
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autoantibodies to insulin, islet cell autoantibodies and antibodies to 
glutamic acid decarboxylase.  
At the time of diagnosis of type 1 diabetes, one or more 
autoantibodies are present in around 90% cases.  
It is associated with other autoimmune conditions like vitiligo, 
addisons disease, pernicious anemia, grave’s disease and Hashimoto’s 
thyroiditis.  
Type 1 diabetes has strong HLA associations which can either be 
protective or predisposing. IDDM 1 gene encoded within HLA region 
remains the most important powerful determinant of type 1 diabetes 
which accounts for approximately 40% of familial inheritance. 
Some patients have permanent insulinopenia and they develop 
diabetic ketoacidosis without any evidence of autoimmunity. It is 
termed as idiopathic diabetes. It is not HLA associated and lacks 
immunological evidence. 
Individuals with this form of diabetes may have episodic 
ketoacidosis and exhibits varying degree of insulin deficiency in between 
the episodes. 
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This figure illustrates the pathophysiology of type 1 diabetes. 
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TYPE 2 DIABETES: 
  Type 2 diabetes mellitus is a heterogenous group of disorders 
characterised by varying degrees of insulin resistance, impaired insulin 
secretion and increased glucose production. This is the most common 
form and remains asymptomatic for years. It is commonly seen in adults 
but can occur in childhood. Although insulin level in these patients 
appears normal/elevated, its level is always low when it is compared with 
elevated plasma glucose level. It has strong genetic predisposition.  
Risk of the disease increases with age, physical inactivity and 
obesity. It occurs more frequently in individuals with hypertension, 
dyslipidemia and in women with prior gestational diabetes.  
EPIDEMIOLOGY: 
According to International Diabetes Federation, 285 million adults 
were estimated to have diabetes in 2010. Prevalence may soar to 438 
million in 2030 if proper prevention and control measures are not 
undertaken. Increase in prevalence is attributed to increasing obesity due 
to physical inactivity and the aging of the population. Type 2 diabetes 
constitutes majority (80 to 95 percent) of adult onset diabetes and its 
incidence is increasing in childhood and juvenile onset disease. Around 
70 percent of people with diabetes live in developing countries (China 
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and Indian subcontinent). The variability in the incidence of both type1 
and type 2 diabetes mellitus is likely due to genetic, behavioural and 
environmental factors. According to Indian council of Medical Research, 
the prevalence of diabetes in India in 2000 was 12 to 19 % in urban and 4 
to 9 % in rural areas. 
AGE OF ONSET: 
 The age of onset of type 2 diabetes mellitus is 4
th
 to 5
th
 decade of 
life however the age of onset has been dropping steadily over the years, 
especially in ethnic groups of high prevalence. In Asia, the characteristics 
of diabetes are different from western countries with lower age of onset, 
low BMI, greater visceral adiposity and a reduced insulin secretory 
capacity. There is no sex predilection. 
RISK FACTORS FOR TYPE 2 DIABETES MELLITUS: 
 Positive family history 
 Race/ethnicity (pacific islands , African American, Asians) 
 Physical inactivity 
 Obesity( BMI ≥ 25 kg/m2 ) 
 History of GDM or delivery of baby >4 kg 
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 Hypertension 
 H/o cardiovascular disease 
 HDL  <35 mg/ dl and/or triglycerides > 250 mg/dl 
 Polycystic ovary syndrome or acanthosis nigricans20 
 
 
 
 
This diagram illustrates the effects of insulin in various organs 
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GENETIC CONSIDERATIONS OF TYPE 2 DIABETES 
MELLITUS: 
 Type 2 diabetes mellitus is a disorder with a strong genetic 
component. The concordance in identical twins is 70 to 90 percent. The 
risk of developing disease in an individual approaches to 40 percent if 
both parents are diabetic. Genetically type 2 diabetes mellitus has both 
monogenic and polygenic forms. 
 Now 36 genetic loci has been identified which contributes to risk of 
type 2 diabetes. Incidence is high among Latinos/Hispanics, aboriginal 
people in America and Australia, Indian and Pacific ocean island 
populations and people of Indian subcontinent
21
. 
 The genes predisposing to type 2 diabetes mellitus are not 
completely identified. For now, around 20 candidate genes are screened 
for association with type 2 diabetes mellitus of which calpain-10, 
peroxisome proliferator activated receptor-gamma, transcription factor 7-
like 2 gene , Kir 6.2 and hepatocyte nuclear factor-4α are important. 
Many of them predispose to obesity which in turn lead to diabetes. These 
susceptibility genes are likely to cause the disease by altering islet 
function or insulin secretion. In non-obese Asian Indians ENPP-1 K121Q 
is one of the susceptibility genes and it causes insulin resistance. 
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MONOGENIC FORMS OF TYPE 2 DIABETES MELLITUS: 
 The genetic etiology is clear in this form of type 2 diabetes 
mellitus. They show an autosomal dominant inheritance. 
 Phenotype characterised by defective insulin secretion 
  - Maturity onset diabetes of the young (MODY) 
 - Mutations in the insulin or proinsulin genes 
 - Mitochondrial gene mutations 
 Phenotype characterised by insulin resistance 
- Lipoatrophic diabetes 
- Mutations in insulin receptor gene 
o Type A insulin resistance 
o Leprechaunism 
o Rabson- Mendenhall syndrome 
- Mutations in the PPAR- gamma gene 
ENVIRONMENTAL FACTORS: 
 Increased caloric consumption 
 Medications 
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 Stress 
 Decreased exercise 
The disease is caused by the interaction of adverse environmental factors 
with genetic factors i.e., altering the expression of genes.  
INSULIN RESISTANCE: 
It is defined as ‘decrease in the activity of endogenous or 
exogenously administered insulin to alter the metabolism in target 
tissues’22. Most of the individuals will maintain normal glucose level by 
increasing insulin production by beta cells to compensate for decrease in 
action of insulin. In susceptible individuals, there is failure of beta cells to 
maintain high level of insulin secretion or increasing in insulin resistance 
which results in progressive glucose intolerance and subsequent 
development of diabetes. Genetic factors play a role in both in propensity 
to develop insulin resistance and beta cell failure in response to insulin 
resistance. 
Sites of insulin resistance: 
 Skeletal muscle 
 Adipose tissue 
 Liver  
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Mechanism of insulin resistance: 
Alteration in tyrosine kinase phosphorylation , altered post receptor 
events and other signal regulatory proteins are responsible for the 
resistance. It is also due to abnormal insulin or insulin receptor. Sustained 
hyperglycemia can cause failure to enhance hexosamine pathway that 
leads to glucotoxicity resulting in increased glucosamine level. Increased 
glucosamine produce insulin resistance in both skeletal muscle and 
adipose tissue. Sustained hyperinsulinemia produce insulin resistance by 
down regulation of insulin receptor. Main site of insulin resistance occurs 
in post receptor level.  
The beta subunit in insulin receptor undergoes serine-threonine 
phosphorylation besides tyrosine autophosphorylation. It is responsible 
for increasing insulin resistance and therefore it impairs signal 
transduction. In insulin resistance state, the GLUT-4 is not depleted, but 
its translocation is hampered. 
Type 2 diabetes is often associated with other conditions like 
obesity, hyperlipidemia and hypertension. 
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This figure illustrates the pathophysiology of type 2 diabetes & insulin 
resistance 
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Type 2 diabetes                 obesity 
Insulin resistance 
  
 
 
Hypertension       Hyperlipidemia 
     
 
 
 
DEFECTS IN INSULIN SECRETION: 
 Insulin sensitivity is an important factor in determining the 
magnitude of insulin response to beta cell stimulation by glucose. Pattern 
of insulin release is abnormal. First phase of insulin release is absent or 
blunted, whereas second phase is enhanced and prolonged, resulting in 
hyperinsulinemia. 50% of beta cell function is already lost at the time of 
diagnosis. In islets, free fatty acid (FFA) is required for insulin 
Hyperinsulinemia 
Insulin resistance 
Atherosclerosis 
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production. However excess FFA result in reduction of glucose 
stimulated insulin release. 
INITIAL EVALUATION OF PATIENT WITH DIABETES: 
Medical history: 
 Age of onset of disease 
 Family history 
 Eating patterns and nutritional status 
 Growth and development in children and adulthood 
 Diabetes education history 
 Previous treatment regimens and its response 
 Current treatment ( including medication, physical activity, meal 
plan) 
 History of diabetes related complications 
o Microvascular: nephropathy, retinopathy, neuropathy 
(sensory, including history of foot lesion; autonomic, 
including sexual dysfunction and gastroparesis) 
o Hypoglycaemia awareness 
o Any severe hypoglycaemia : frequency and cause 
o Macrovascular: CAD, CVA, peripheral arterial disease 
o Others: psychosocial problems, dental disease 
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 Other endocrine disorders 
Physical examination: 
 Height , weight, BMI 
 Blood pressure ( including orthostatic measurement) 
 Fundus examination 
 Thyroid palpation 
 Skin examination ( for insulin injection site & acanthosis nigricans) 
 Complete foot examination: 
 Inspection 
 Palpation of dorsalis pedis and posterior tibial artery 
 Presence/absence of patellar and ankle reflex 
 Determination of proprioception, vibration and 10g monofilament 
test. 
Lab evaluation: 
 Fasting lipid profile 
 Liver function test 
 Spot PCR 
 Serum creatinine and eGFR 
 HbA1c 
 Thyroid function test 
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Referrals: 
 Annual dilated eye exam 
 Family planning for women of reproductive age 
 Registered dietitian for medical nutritional therapy 
 Diabetes self management education 
 Dental examination 
 Mental health professional(if needed) 
GESTATIONAL DIABETES: 
It is glucose intolerance developing during pregnancy. About 50% of 
women with GDM (Gestational Diabetes Mellitus) develop type2 
diabetes in their later life. So, screening for gestational diabetes is 
recommended in all pregnant women, who are not known to have 
diabetes, between 24
th
 and 28
th
 week of pregnancy.  
A 75-g OGTT is done in the morning after overnight fasting for at 
least 8 hours with plasma glucose monitoring at fasting, 1 hour and 2 
hours. Diagnosis of gestational diabetes is made if any of the values are 
exceeded. 
  Fasting : ≥ 92 mg/ dl ( 5.1 mmol/ L) 
 1 hour : ≥ 180 mg/ dl ( 10.0 mmol/L) 
  2 hour: ≥ 153 mg /dl (8.5 mmol/L) 
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Screening For Gestational Diabetes: 
Risk assessment at 1
st
 prenatal visit: 
o Marked obesity 
o Previous GDM 
o Glycosuria 
o Features suggestive of diabetes 
If testing is negative, re-testing should be done at 24 to 28 weeks of 
gestation. 
During initial prenatal visit, if high risk women is found to have 
diabetes by using standard criteria for diabetes, they should receive a 
diagnosis of ‘overt’ diabetes, not gestational diabetes.  
EFFECTS OF MATERNAL HYPERGLYCEMIA ON FOETUS: 
In first trimester: 
- Growth retardation 
- Foetal wastage 
- Malformations 
In second trimester: 
- Foetal loss 
52 
 
- Pre-eclampsia 
- Polyhydramnios 
- Hypertrophic cardiomyopathy 
- Placental insufficiency 
In third trimester: 
- Respiratory distress syndrome 
- Macrosomia 
- Hyperbilirubinemia 
- Hypomagnesemia 
- Hypocalcemia 
- Intrauterine death 
DIAGNOSIS OF DIABETES MELLITUS: 
Criteria for screening 
23
: 
 Fasting plasma glucose > 100 mg/dl 
 Random plasma glucose > 130 mg/dl 
 HbA1c > 6.0% 
- If screening test is negative, again screening should be done in 3 
years 
- If screening test is positive, but the result is below diagnostic 
threshold- do another test using different method for diagnosis 
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- If screening test is positive and the result is above the diagnostic 
threshold but the second test does not reach the threshold, again do 
test in one year. 
Criteria for diagnosis: 
  Fasting plasma glucose > 126 mg/dl 
 Random plasma glucose > 200mg/dl 
 2 hour OGTT > 200mg/dl 
 HbA1c > 6.5% 
- Diagnosis requires confirmation, unless equivocal symptoms 
of hyperglycemia are present. 
Interpretation of HbA1c: 
Normal        : < 5.7% 
Pre-diabetes: 5.7 % to 6.4 % 
Diabetes       : 6.5% or more 
COMPLICATION OF DIABETES: 
ACUTE: 
1. Hypoglycemia:  occurs in patients treated with insulin or insulin 
secretagogues. It is due to disturbance in balance between food 
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intake and appropriate drug dosage. Exercise, alcohol intake and 
decreased liver/kidney function precipitate this imbalance. 
2. Hyperosmolar hyperglycemic nonketotic syndrome24- 
characterised by  
(a) severe hyperglycemia( blood glucose > 600mg/dl) 
(b) absence of significant ketosis 
(c) serum hyperosmolality (>340mOsm/kg) 
(d) profound dehydration 
Typically the patient develops altered sensorium, excessive thirst and 
signs of severe dehydration. 
Precipitating causes are 
o Infection 
o Diabetic gangrene 
o UTI 
o Septicaemia 
o Extensive burns 
o Myocardial infarction 
o Pancreatitis 
o Alcoholism 
o Peritoneal and hemodialysis 
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o Surgical stress 
o Drugs like steroids, immunosuppressive agents. 
Dehydration, electrolyte abnormalities, hyperglycemia and 
hyperosmolar condition should be corrected with appropriate 
fluids, insulin and potassium. 
3. Diabetic ketoacidosis-  
Characterised by 
(a) Hyperglycemia 
(b) Hyperketonemia 
(c) Metabolic acidosis 
4. Infection – common infections in diabetes are tuberculosis, 
malignant otitis externa, pyelonephritis, pneumonia, staphylococcal 
infection, periodontal infection, candidiasis, mucormycosis, 
hepatitis C, HIV infection. 
5. Lactic acidosis- when lactic acid level is more than 5 mmol/L in 
the blood. 
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This diagram represents the formation of ketone bodies in untreated 
diabetes 
 
CHRONIC: 
MACROVASCULAR COMPLICATION: 
o CAD (Coronary Artery Disease) 
o PAD (Peripheral Arterial Disease) 
o CVA ( Cerebro Vascular Accident ) 
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About 75 to 80 percent of all diabetic patients will die prematurely due 
to cardiovascular disease (CVD), particularly CHD (Coronary Heart 
Disease). 
 Cardiovascular disease: 
Adults with diabetes have heart disease death rates about 2 to 4 
times more than that of adults without diabetes. Type 2 diabetes patients 
have 3 to 6 fold increase in rate of myocardial infarction. Common co-
existing conditions like obesity, hypertension, dyslipidemia (decrease 
HDL, increase triglycerides, altered LDL particle size and number), 
hypercoagulability are also cardiovascular risk factors. 
 Cerebrovascular disease: 
TIA (Transient Ischemic Attack) and stroke are more common in 
diabetics than non-diabetics. Haemorrhagic stroke is less common. 
Prognosis is worse in diabetic patients. Recurrent stroke and stroke 
related dementia are frequent in diabetics. 
 Peripheral arterial disease: 
It is 2 to 3 times more common in diabetic males and 5 to 6 times 
more common in diabetic females. Clinical feature include intermittent 
claudication pain, critical limb ischemia and gangrene. 
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MICROVASCULAR COMPLICATIONS: 
 Diabetic Retinopathy: 
 The risk of developing retinopathy depends upon duration of 
diabetes and degree of hyperglycemia. It starts from hyperglycemia 
induced vascular injury. Histological lesion is thickening of basement 
membrane in retinal capillaries and loss of pericytes. It is classified as 
proliferative and non-proliferative diabetic retinopathy. Most of the 
patients are asymptomatic in initial stages. Since the onset and duration of 
disease is unknown in type 2 diabetes, fundus examination should be 
done at the time of diagnosis. Most common cause of vision loss in these 
patients is due to development of macular edema. 
The ETDRS study (Early Treatment of Diabetic Retinopathy Study) 
defined CSME (Clinically Significant Macular Edema) as follows
25
: 
 Retinal thickening at/within 500 µm from the centre of macula 
 Hard exudates at/within 500 µm from the centre of macula ( if 
associated with thickening of adjacent retina) 
 Zones of retinal thickening at least 1 disc area in size, part of which 
is within 1 disc diameter of the centre. 
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  All patients with diabetes (both type 1 and type 2) are at risk of 
developing retinopathy. Early detection and appropriate management can 
reduce the risk of visual loss in these patients. 
 Diabetic neuropathy: 
 Classification: 
 Symmetrical polyneuropathies: 
- Large fibre  neuropathy 
- Small fibre neuropathy 
- Autonomic neuropathy 
- Distal sensory polyneuropathy 
 Asymmetrical neuropathies: 
- Cranial neuropathy 
- Truncal neuropathy 
- Lumbosacral radiculopathy 
- Limb mononeuropathy 
- Entrapment neuropathy 
 Combinations: 
- Polyradiculo neuropathy 
- Diabetic neuropathic cachexia 
- Symmetrical polyneuropathies 
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According to the American Academy of Neurology, diabetic 
neuropathy is diagnosed in the presence of autonomic or somatic 
neuropathy when other causes causing neuropathy are excluded. At least 
two out of five criteria are needed to diagnose: symptoms, signs, electro- 
diagnostic testing, quantitative autonomic and sensory testing. Bed side 
examinations include sensation of pin prick, assessment of muscle pain, 
touch, temperature, vibration and tendon reflexes. Compound action 
potential amplitude is initially normal, as the disease progresses it 
declines. Treatment is aimed to prevent progression of neuropathy and to 
provide symptomatic relief. Based on the evidence that it has an 
autoimmune basis, immunosuppressive therapies like immunoglobulin, 
corticosteroids and plasma exchange has been tried in lumbosacral 
radiculoneuropathy. 
 Diabetic nephropathy: 
 It is characterised by excessive albumin excretion in urine due to 
loss of kidney function. The hallmark of diabetic nephropathy is 
proteinuria. Mechanism of proteinuria – Increased filtration, increased 
tubular secretion and decreased tubular absorption. It is the leading cause 
for ESRD (End Stage Renal Disease). Most of the diabetic patients 
suffering from advanced renal disease require renal replacement therapy. 
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 Diabetic foot: 
Classical triad: 
- Neuropathy 
- Ischemia 
- Infection 
Wagner’s classification: 
Grade 0: No ulcer in high risk foot 
Grade 1: Superficial ulcer 
Grade 2: Deep ulcer penetrating upto tendon/bone/joint 
Grade 3: Deep abscess/osteomyelitis 
Grade 4: Localised gangrene 
Grade 5: Extensive gangrene that requires amputation 
Warning symptoms of diabetic foot: 
 Vascular: 
- Cold feet 
- Intermittent claudication 
- Pain at rest, especially nocturnal 
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 Neurologic: 
- Burning/tingling sensation 
- Pain and hypersensitivity 
- Cold feet 
- Weakness 
- Diminished sweating 
 Musculoskeletal: 
- Gradual change in foot shape 
- Sudden painless change in foot shape without history of 
trauma. 
 Dermatological: 
- Painless wounds 
- Slow healing/ non healing wounds 
- Chronic scaling, itching 
- Recurrent infection(paronychia, athlete’s foot) 
FACTORS CONTRIBUTING TO FOOT ULCER: 
Extrinsic factors: 
- Inappropriate foot wear 
- Object inside the shoes 
-  Walking bare foot 
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- Sharp injuries 
- Falls and accidents 
Intrinsic factors: 
- Joint deformity 
- Callus 
- Limited joint motility 
- Bony prominences 
- Fissures 
- Previous foot surgery 
CHARCOT FOOT: 
Charcot joint is defined as relatively painless progressive 
arthropathy of single/ multiple joints. Most common site is tarsal-
metatarsal region. Other sites are metatarsophalangeal joint, ankle and 
subtalar joint. Usually, minor trauma is the precipitating event.  
Prevention of diabetic foot includes: 
o  Primary prevention – screening of high risk foot and advice on 
preventive footwear 
o Secondary prevention – management of foot lesion 
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o Tertiary prevention – prompt referral to specialist for advanced foot 
lesion. 
METABOLIC SYNDROME: 
Type 2diabetes and glucose intolerance are also the manifestations in 
metabolic syndrome
26
. 
Diagnosis of metabolic syndrome: 
ATP III criteria: (three or more of the following) 
1. Abdominal obesity- waist circumference  >102cm(male) and 
>88cm(female) 
2. Hypertriglyceridemia  ≥ 150 mg/dl 
3. Low HDL : < 40mg/dl(male) and <50mg/dl(female) 
4. High BP: ≥ 130/85 mm Hg 
5. High fasting glucose : ≥ 110mg/dl 
WHO criteria: 
1. High blood pressure : ≥ 160/90 mm Hg 
2. Hyperlipidemia : TGL > 150mg/dl ., HDL < 35 mg/dl 
3. Central obesity: waist to hip ratio > 0.90 (men) and >0.85(women) 
or BMI > 30 kg/m
2
 
4. Microalbuminuria: urine albumin excretion rate ≥20µg/min 
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MANAGEMENT: 
  
Major management goals are 
  To prevent both micro and macrovascular complications. 
 To avoid symptoms due to drug adverse effects, 
hyperglycemia and its complications. 
Specific goals of therapy: 
 Elimination of symptoms 
 Optimizing glycemic parameters 
 Achieve and maintaining a ideal body weight 
 Maintaining blood pressure control 
 Maintain optimal lipid profile 
 Achieve optimal health and well-being 
Recommended treatment modalities: 
 Diet modification 
 Exercise 
 Pharmacological intervention 
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Recommended targets for adults with diabetes: 
 Glycemic control  : A1c <7 
 Preprandial plasma glucose : 70 to 130 mg/dl 
 Postprandial plasma glucose: <180mg/dl 
 Blood pressure: <130/80mmHg 
 LDL cholesterol : <100mg/dl 
 HDL cholesterol : >40mg/dl 
 Triglycerides : <150mg/dl 
Medical nutritional therapy: 
  Since obesity is the major risk factor, nutritional therapy is 
the cornerstone in treating type 2 diabetes
27
. A registered 
dietition expertise in diabetes is the team member to deliver 
Medical Nutritional Therapy (MNT) 
It involves 
  Assessment : evaluation of individual life style and his food 
intake 
 Goal setting: goals to be set in which areas that person needs 
improvement 
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 Intervention : by nutritional plans, life style change and 
exercise 
 Evaluation 
 Monitoring progress and measure outcome indicators 
Goals of MNT: 
- To achieve normal range in glucose level 
- To achieve normal lipid profile 
- To achieve ideal range of BP 
- Improving the quality of life 
Nutritional intervention and recommendations: 
  Modest weight loss ( 5 to 7%) shown to improve insulin 
resistance 
 Physical activity and behaviour modification helpful in 
maintenance of lost weight 
 Effective meal plan 
 Weight loss medications in obese and overweight persons 
(combined with life style changes) 
 Bariatric surgery when BMI > 35kg/m2   
 Five non nutritive sweeteners approved by FDA ( saccharin, 
aspartame, acesulfame K , neotame, sucralose) 
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 Protein intake of 15% to 20% of total energy intake is 
sufficient. 
 Limit saturated fat to less than 7% 
 Minimise the intake of trans fatty acid 
Exercise: 
Benefits of increased physical activity: 
 Improves insulin sensitivity and glucose tolerance 
 Weight loss and maintenance of ideal body weight 
 Improved cardiovascular risk factors 
 Enhanced work capacity 
 Reduction in insulin dosage or need for insulin/drugs 
 Improving the sense of well-being and quality of life 
Medical evaluation should be done before prescribing exercise 
and it includes 
 Determination of glycemic control 
 CVS examination( BP, peripheral pulse, bruit) 
 Neurological examination 
 Dilated fundus examination especially if proliferative 
diabetic retinopathy is suspected/present 
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Precautions for patients with complications: 
  Insensitive feet / peripheral vascular insufficiency 
 Avoid running 
 Choose cycling, walking or swimming 
 Proper foot wear and daily foot examination should be 
emphasised 
 Untreated/ recently treated proliferative retinopathy 
          Avoid exercise associated with 
 Valsalva maneuvers 
 Rapid head movements 
 Increased intra-abdominal pressure 
 Hypertension 
 Avoid valsalva maneuvers 
 Avoid heavy lifting 
 
The patient should start exercise slowly and then at regular 
intervals at least three to four times a week and then gradually 
increase the intensity, duration and frequency of exercise. 
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Aerobic exercise (biking, swimming, dancing, jogging) 
should be encouraged. In persons who are confined to chair, 
armchair exercise can be performed. 
To improve glycemic control, at least 75 min/ week of 
vigorous aerobic exercise or 150 min/ week of moderate intensity 
aerobic exercise are recommended. Physical activity should be 
recommended for at least 3 days/week and not more than 2 
consecutive days without physical activity. 
Exercise increase the sensitivity of insulin in skeletal muscle 
and increases the glucose uptake. In high risk persons, regular 
exercise may delay/ prevent the progression of diabetes. 
Pharmacological intervention: 
 Pharmacological intervention is an adjunct to but not as a 
substitute for exercise and dietary modification. At the time of 
diagnosis, metformin therapy should be started concurrently along 
with life style intervention.  
 The choice of antidiabetic agents is individualized according 
to patient’s preference, contraindications/ comorbidities, social 
support and finances. 
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ORAL ANTIDIABETIC AGENTS: 
 It differs from one another in physiological effect, 
mechanism of action, pharmacokinetics and metabolism. 
  Insulin secretagogues (sulfonylureas, repaglinide and 
nateglinide) stimulate insulin secretion from beta cells. 
 Biguanides ( metformin) reduces hepatic overproduction of 
glucose. 
 Alpha glucosidase inhibitors inhibit the absorption of 
carbohydrate from intestine. 
 Thiazolidinediones primarily work in fat and muscle and 
enhance insulin action. 
 Amylinomimetics increase the activity of amylin with 
effects on weight and glucose. 
 Incretin mimetics increase GLP-1 (Glucagon like peptide) 
activity with effects on glucose and weight. 
 DPP-4 ( DiPeptidyl Peptidase IV) inhibitors increase the 
level of incretin hormones. 
 In most of the patients, combination of these drugs is 
required to achieve target glycemic control. 
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SULFONYLUREAS: 
 Mechanism of action: It binds with SUR (sulfonyl urea 
receptor) which is present in ATP dependent potassium channel. 
 It is the drug of choice when life style intervention and 
metformin fails to achieve target glycemic control. Good 
responders include: (A) FBS< 200mg/dl, (B) preserved beta cell 
mass, (C) short duration of diabetes, (D) normal weight subject. 
 It is contraindicated in pregnancy, type 1 diabetes, severe 
infections and allergy to sulpha drugs. 
 Adverse effects are weight gain, hypoglycaemia, and 
hypersensitive reaction. 
NON-SULFONYLUREA SECRETAGOGUES:  
 Mechanism of action is almost similar to that of 
sulfonylureas but the difference is that in binding site. It binds in 
SUR 1 subunit in ATP dependent potassium channel. 
 It is contraindicated in liver and renal disease. 
 Adverse effects are weight gain and hypoglycaemia (less 
common than sulfonylureas). 
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BIGUANIDES: 
 Metformin decreases hepatic glucose production by 
inhibiting hepatic gluconeogenesis and glycogenolysis. It increases 
the GLUT 4 (insulin sensitive) translocation to the cell membrane. 
 According to ADA guidelines, metformin is to be given in 
all type 2 diabetic patients in the absence of contraindications. 
 It is contraindicated in hepatic dysfunction, serum creatinine 
>1.5mg/dl, metabolic acidosis, alcohol abuse and congestive heart 
failure. 
 It should be withheld 24 hours prior to surgery and any 
radiological procedures that require contrast agents. 
 Adverse effects are dysguesia, nausea, vomiting, lactic 
acidosis and vitamin B12 deficiency. 
THIAZOLIDINEDIONES: 
 It is found to be a ligand for PPAR-γ (Peroxisome 
Proliferator Activated Receptor Gamma). Main action : Increase in 
adipogenesis and increase in insulin sensitive mediated glucose 
uptake in muscle. It is more useful in patients with insulin 
resistance.  
74 
 
 It is contraindicated in liver disease and congestive heart 
failure. 
 Adverse effects are weight gain, oedema, anaemia, decrease 
bone mineral density and precipitation of heart failure. 
ALPHA-GLUCOSIDASE INHIBITORS: 
 It is a competitive suppressant of alpha glucosidase, an 
enzyme that hydrolyses polysaccharides to monosaccharides, 
which is present in small intestine brush border. It can be used in 
combination with other drugs. 
 It is contraindicated in gastroparesis, inflammatory bowel 
disease and serum creatinine > 2mg/dl. 
 Adverse effects are diarrhoea, flatulence, abdominal 
discomfort and distension. 
INSULIN PREPARATIONS: 
CONVENTIONAL INSULIN: 
1. Short acting insulin – regular insulin( human) 
o Onset of action : 30 mins to 1 hour 
o Peak in 2 to 3 hours 
o Duration of action is 6 to 8 hours. 
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2. Intermediate acting insulin- NPH ( Neutral Protamine 
Hagedorn)  
o Onset of action: 1.5 hours 
o Peak in 4 to 10 hours 
o Duration of action is 16 to 24 hours 
INSULIN ANALOGUES: 
1. Rapid acting insulin: 
 Insulin lispro 
o Proline- lysine conversion in beta chain 
o Onset of action : 0.2 to 0.5 hours 
o Peak in 0.5 to 2 hours 
o Duration of action is 3 to 4 hours 
 Insulin aspart 
o Aspartic acid for proline substitution in beta chain 
o Onset of action: 0.2 to 0.5 hours 
o Peak in 0.5 to 2 hours 
o Duration of action is 3 to 5 hours 
 Insulin glulisine 
o Lysine for asparagine substitution in beta chain 
o Onset of action : 0.2 to 0.5 hours 
o Peak in 1 hour 
76 
 
o Duration of action is 4 hours 
2. Long acting insulin: 
 Insulin glargine 
o Prolonged beta chain and glycine for asparagine 
substitution in alpha chain 
o pH: 4 
o Onset of action : 2 to 4 hours 
o Duration of action : 20 to 30 hours 
o Not approved for pregnant patients and children < 6 
years of age 
 Insulin detemir 
o Acylation of lysine with saturated fatty acid in beta 
chain 
o Onset of action : 1 to 2 hours 
o Duration of action : 20 hours 
INDICATION OF INSULIN THERAPY IN TYPE 2 
DIABETES: 
 FBS> 250mg/dl 
 HbA1C>10% 
 Patients with osmotic symptoms/ketosis 
 During inter-current illness 
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 Patient undergoing surgery 
 During pregnancy 
ADVERSE EFFECT OF INSULIN THERAPY: 
 Hypoglycaemia ( common) 
 Weight gain 
 Lipoatrophy ( rare) 
 Lipohypertrophy (rare) 
 Insulin allergy (rare) 
ASSESSMENT OF TREATMENT EFFICACY: 
 It should be monitored through a schedule of patient interviews and 
examinations with comprehensive assessment of: 
 Continued patient acceptance of treatment plans and goals 
 Symptoms 
 Weight 
 Blood pressure 
 Smoking 
 Screening evaluations include 
- Lipid levels 
- Urine microalbumin to creatinine ratio 
- Dilated eye exams 
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- Comprehensive foot examination 
 Various parameters of glycemic control. 
Patient can determine the effects of glycemic therapy by SMBG (Self 
Monitoring of Blood Glucose). They can use a daily journal to record 
food intake, exercise, doses of insulin/oral hypoglycaemic agent, 
symptoms and results of SMBG. 
Multiple therapeutic agent and problem solving using SMBG results 
should make it possible for most patients to achieve glycemic control 
goals. 
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MATERIALS AND METHODS 
STUDY POPULATION:  
This study was conducted in 100 diabetic patients and 100 non- diabetic 
healthy controls who attended General Medicine OPD at Government 
Rajaji Hospital, Madurai. 
Inclusion criteria: 
1. Age 30 to 70 years 
2. Positive History of diabetes 
Exclusion criteria: 
1. Hypertension 
2. Gastrointestinal disorders 
3. Impaired renal function 
4. Alcoholic pancreatitis 
5. Therapy with diuretics, aminoglycosides 
6. Endocrine disorders 
7. Heart disease 
8.  Not willing to give consent 
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DATA COLLECTION: 
A detailed history with detailed clinical examination was done. 
LABORATORY INVESTIGATIONS: 
1. Fasting blood glucose 
2. Postprandial blood glucose 
3. Serum magnesium 
4. HbA1c 
5. Serum urea and creatinine 
6. Urine analysis 
7. ECG 
 
STUDY PROTOCOL: 
100 diabetic patients and 100 non diabetic healthy controls in the 
age group of 31 to 70 years attending General Medicine OPD were 
included. Blood samples were taken from each of the study groups and 
magnesium levels are assessed and compared between the case and 
control groups. 
Blood pressure was recorded. Cardiovascular disease was ruled out 
by history and ECG. Urine was examined for proteinuria.FBS values 
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were assessed after 8 hours of fasting. PPBS values, Blood urea and 
serum creatinine values were measured.  
Serum magnesium was determined by using photometric method. 
Calmagite – a metallochromatic indicator when binds with magnesium in 
alkaline medium, it forms red colour complex and it is measured at 530 to 
550 nm. To prevent interference by calcium, specific calcium chelating 
agent EGTA is added. To avoid the heavy metal complex formation,KCN 
is added. Polyvinylpyrrolidone and surfactant are also included to reduce 
the interference from lipemia and protein. Intensity of colour formed is 
directly proportion to the amount of magnesium present in the sample. 
DESIGN OF STUDY: 
Case control study 
PERIOD OF STUDY: 
6 months (April 2014 to September 2014) 
COLLABORATING DEPARTMENTS: 
Department of Medicine 
Department of Biochemistry 
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ETHICAL CLEARANCE:  
The study was approved by the Institutional Ethical Committee. 
CONSENT: Individual written and informed consent. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT: NIL 
ANALYSIS:  STATISTICAL ANALYSIS 
The data collected was tabulated in a master chart. Statistical 
analysis was done by using Epidemiological Information Package (EPI 
2010) developed by Centre for Disease Control, Atlanta, SPSS 20 and 
Sigma Stat 3.5 version. The association between means of continuous 
variables was assessed by using one way ANOVA test and independent 
student’s t test and that of categorical variables with chi square test. A p 
value of less than 0.05 was taken as significant. 
PARTICIPANTS:  
100 diabetic patients and 100 age and sex matched non- diabetic 
controls attended General Medicine OPD at Government Rajaji Hospital, 
Madurai. 
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RESULTS 
 
Table 1: AGE DISTRIBUTION 
  
Age in years Cases Controls 
Number Percentage Number Percentage 
31 - 40 14 14.0 15 15.0 
41 - 50 42 42.0 40 40.0 
51 - 60 24 24.0 26 26.0 
61 - 70 20 20.0 19 19.0 
Total 100 100.0 100 100.0 
Mean ±SD 50.39±9.76 50.01±10.15 
The mean age of cases and controls were 50.39±9.76 and 50.01±10.15 years 
respectively. The maximum number of patients was in the age group of 41-50.  
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Figure 1: AGE DISTRIBUTION 
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Table 2: SEX DISTRIBUTION 
 
 
 
 
 
 
 
Both among the cases and controls, the sex distribution were same i.e., 
70% males and 30% females. 
 
  
Sex Cases Controls 
Number Percentage Number Percentage 
Male 70 70.0 70 70.0 
Female 30 30.0 30 30.0 
Total 100 100.0 100 100.0 
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Figure 2: SEX DISTRIBUTION 
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Table 3: MEAN PATTERN OF FBS 
 
FBS(mg/dl) Mean SD ‘p’ value 
Cases 102.42 11.16 
 
<0.001 Controls 91.93 4.32 
 
Table 4: MEAN PATTERN OF PPBS 
 
PPBS(mg/dl) Mean SD ‘p’ value 
Cases 187.02 30.59 
<0.001 Controls 123.83 7.63 
 
The mean FBS level among cases and control were 102.42±11.16 mg/dl 
and 91.93±4.32 mg/dl respectively. 
The mean PPBS level among cases and control were 187.02±30.59 mg/dl 
and 123.83±7.63 mg/dl respectively. 
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Figure 3: MEAN PATTERN OF FBS 
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Figure 4: MEAN PATTERN OF PPBS 
 
 
The mean PPBS level among cases and control were 187.02±30.59 mg/dl 
and 123.83±7.63 mg/dl respectively. 
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Table 5: COMPARISON OF SERUM MAGNESIUM LEVEL 
BETWEEN CASES AND CONTROLS 
 
 
  
Serum 
Magnesium(mEq/L) Mean SD ‘p’ value 
Cases 1.29 0.42 
<0.001 Controls 1.96 0.25 
There was significant difference between levels of serum magnesium levels 
among cases and controls. The mean serum magnesium levels of cases and 
controls were 1.29±0.42 mEq/L and 1.96±0.25 mEq/L respectively. 
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Figure 5: COMPARISON OF SERUM MAGNESIUM LEVEL 
BETWEEN CASES AND CONTROLS 
 
 
 
 
 
The mean serum magnesium level in cases and controls were 1.29±0.42 
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Table 6: COMPARISON OF SERUM MAGNESIUM LEVEL 
BETWEEN CONTROLLED AND UNCONTROLLED DIABETES 
 
 
HbA1C(%) 
 
 
 
 
Cases 
Serum Magnesium 
level(< 1.3 mEq/L) ‘p’ value 
< 7 61 25 
0.01 ≥ 7 39 39 
 
  
There was significant difference between magnesium levels among 
controlled and uncontrolled diabetics. Magnesium level was 
significantly lower in uncontrolled than that of controlled diabetics. 
93 
 
Figure 6: 
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0.99±0.09 mEq/L and 1.48±0.42 mEq/L respectively. The difference was 
statistically significant based on standard error between two means. 
Statistical methods: 
Student T test has been used to find the significance of serum magnesium 
levels between cases and controls.  
Chi – square test is used to find the significance of mean serum 
magnesium level among controlled and uncontrolled diabetics. 
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DISCUSSION 
This study was conducted in Government Rajaji Hospital, Madurai 
in  patients who were attending General Medicine Outpatient department. 
This study has enrolled a total of 100 cases and 100 healthy controls who 
were age and sex matched. 
AGE DISTRIBUTION: 
In the present study, the mean age group of cases and controls were 
50.39 ± 9.76 and 50.01 ± 10.15 respectively. The minimum age was 31 
years and maximum age was 70 years. Maximum number of patients are 
in the age group of 41 to 50 i.e., 42%.  
In the study done by Maula MG et al conducted in 2013, the mean 
age of cases and controls were 48.08 and 47.74 years respectively and the 
total numbers of study subjects were 50.  
In the study done by Shrabani Mohanty et al in Bangalore (2013), 
the mean age of cases and controls were 54.36±11.25 and 51.81±10.25 
respectively and the total numbers of study subjects were 100. The mean 
age of diabetic population is 4
th
 to 5
th
 decade in the present as well as 
previous studies. 
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SEX DISTRIBUTION: 
In this study, out of 100 cases, 70% were males and 30% were 
females. 
 In the study conducted by Maula MG et al
28
 in 2013, among 50 
cases, 58% were males and 42% were females. In the study conducted by 
Shrabani Mohanty et al in Bangalore (2013), among 100 cases 70% were 
males and 30% were females.  
In the study conducted by Monika K et al in Switzerland, among 
109 cases 70% were males and 30% were females. 
 
SERUM MAGNESIUM IN DIABETICS AND CONTROLS: 
In this study, the mean magnesium level in cases and controls were 
1.29 ± 0.42 and 1.96 ± 0.25 and it is found to be significant (p<0.001).  
 The study conducted by Shrabani Mohanty et al in Bangalore has 
shown that serum magnesium in diabetics (1.58±0.28) is significantly 
lower( p<0.001) when compared to controls(1.91±0.22). 
In the study conducted by Ashima Badyal et al in Haryana (2011), 
it is shown that serum magnesium level is significantly lower (p< 0.001) 
in diabetics (1.62±0.47) when compared to healthy controls (2.33±0.37). 
97 
 
In the study conducted by Nadler JL et al
29
, the mean magnesium 
level in cases and controls were 1.94±0.05 and 2.31±0.12 respectively. 
This study shows that intracellular magnesium concentration in diabetics 
were significantly reduced when compared to controls and oral 
magnesium supplementation for 8 weeks restored RBC magnesium 
concentration to normal.  
In the study conducted by Nagase N et al
30
, serum magnesium level 
of diabetics (1.90±0.37) was significantly lower than that of normal 
controls (2.30±0.32). 
In the study done by Maula MG et al in Rangpur, serum 
magnesium level in diabetics were significantly (p<0.001) lower than that 
of healthy non diabetic subjects. 
In the present study, serum magnesium is significantly lower( p < 
0.01) in uncontrolled diabetics than that of controlled diabetics.  In the 
study conducted by Nagase N in Japan, serum magnesium level of poorly 
controlled diabetics is lower than that of well controlled diabetics and this 
result suggest that magnesium deficient state is one of the cause of insulin 
resistance. 
This study has focussed on assessing serum magnesium level at a 
given point of time among diabetic population and the level of 
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magnesium deficiency between controlled and uncontrolled diabetics. 
The study has shown that hypomagnesemia occurs in diabetes mellitus, 
and uncontrolled diabetics have lower level compared to controlled 
diabetics. Since magnesium is involved in various levels of insulin 
secretion, binding and activity, magnesium deficiency decreases insulin 
sensitivity which leads to raised blood sugar levels. 
However in the present study, the amount of dietary intake of 
magnesium (a cause of hypomagnesemia) was not taken into 
consideration because of individual variations in dietary intake and 
magnesium metabolism. The evaluation of effects of oral/ IV magnesium 
towards metabolic control and complications of diabetes related to 
hypomagnesemia were not included in our study. 
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CONCLUSION 
 
1. Serum magnesium levels were lower in type 2 diabetes patients when 
compared to healthy non-diabetic controls. 
2. Levels of serum magnesium in uncontrolled type 2 diabetes were  
lower when compared to controlled diabetic patients. 
Hypomagnesemia is one of the factors in type 2 diabetes which 
leads to various complications. Hence it is worthwhile to estimate 
serum magnesium level in type 2 diabetic patients and 
hypomagnesemia should be corrected to prevent insulin resistance 
and for better glycemic control. 
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SUMMARY 
Estimation of serum magnesium level of 100 patients of type 2 
diabetes and 100 healthy controls who attended OPD in Government 
Rajaji hospital, Madurai was done. 
 
1. The mean age of cases and controls were 50.39±9.76 and 
50.01±10.15 years respectively.  
2. The maximum number of patients was in the age group of 41-50 
(42%) 
3. Among the cases and controls, the sex distribution were same i.e., 
70% males and 30% females. 
4. The mean FBS level among cases and control were 102.42±11.16 
mg/dl and 91.93±4.32 mg/dl respectively. 
5. The mean PPBS level among cases and control were 
187.02±30.59 mg/dl and 123.83±7.63 mg/dl respectively. 
6. The mean serum magnesium level in cases and controls were 
1.29±0.42 mEq/L and 1.96±0.25 mEq/L respectively. i.e serum 
magnesium level among cases were significantly lower than 
controls. 
7. Magnesium level was significantly lower in uncontrolled than 
that of controlled diabetics. 
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PROFORMA 
 
Name:                       Age/Sex:            Occupation: 
 
Presenting illness: 
H/O polyuria, polyphagia, polydipsia, chestpain, sweating, paresthesia, 
blurring of vision, breathlessness, swelling of legs, fatiguability. 
 
Past history: 
H/O smoking, alcohol, hypertension, diabetes, heart disease, ESRD, 
thyroid disease, gout. 
 
Drug history: 
 
Family history: 
 
Clinical examination: 
 
General examination: 
 
Vitals:  Pulse rate: 
              Blood pressure: 
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Systemic examination:  CVS:  
RS:  
ABDOMEN: 
 CNS: 
 
LABORATORY INVESTIGATIONS: 
1. Fasting blood glucose 
2. Postprandial blood glucose 
3. Serum magnesium 
4. HbA1c 
5. Serum urea and creatinine 
6.  Urine analysis 
7.  ECG 
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ABBREVIATIONS 
EGTA - Ethylene Glycol- O,O- bis( 2- aminoethyl) N,N Tetra Acetic acid 
ATP – Adenosine Tri Phosphate 
TRPM - Transient Receptor Potential channel Melastatin member 
KCN - potassium cyanide 
ER- Endoplasmic Reticulum 
PP Cell- Pancreatic Polypeptide cell 
CoA - coenzyme A 
VLDL - Very Low Density Lipoprotein 
HDL – High Density Lipoprotein 
LDL – Low Density Lipoprotein 
GLP - Glucagon Like Peptide 
 GIP - Glucose dependent Insulinotropic Peptide 
GLUT – Glucose Transporter 
PPAR-γ -Peroxisome Proliferator Activated Receptor-Gamma 
MODY- Maturity Onset Diabetes of the Young 
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FFA - Free Fatty Acid 
eGFR- Estimated Glomerular Filtration Rate 
Spot PCR – Spot Protein Creatinine Ratio 
ADA- American Diabetes Association 
Mg – Magnesium 
mg – milligram 
mEq/L –milli Equivalents per litre 
BMI – Body Mass Index 
GDM – Gestational Diabetes Mellitus 
OGTT – Oral Glucose Tolerance Test 
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1 RAMASAMY 32 M 61648 110 213 1.1 7.2 28 0.9 
2 PALANISAMY 41 M 66144 110 210 1.1 7.2 19 0.9 
3 PITACHAI 46 M 59219 96 170 1.5 6.1 26 1.1 
4 PUSHPARAJ 38 M 57114 110 241 1 7.4 18 1.1 
5 PALANI 49 M 66999 98 172 1.9 6 24 1 
6 RAMASAMY 44 M 65111 120 198 1 7.1 20 1 
7 PODHUMPONNU 40 F 55144 92 119 1 6.3 22 0.9 
8 MARUTHUPANDI 47 M 59229 88 174 2 6.1 28 1.1 
9 ARUN 32 M  72646 98 124 1.1 6.4 21 0.9 
10 SELVI 44 F 59325 115 120 1 7.1 27 0.8 
11 THENNARASU 34 M 54114 90 116 1.9 6.3 21 1 
12 MUTHU 52 M 67100 110 230 1.1 7.1 29 0.9 
13 CHELLADURAI 45 M 65122 90 180 2.1 6.3 26 0.9 
14 PATTAMMAL 42 F 65655 126 211 1 7.3 20 0.7 
15 PALANIAPPAN 52 M 60001 114 210 1 7.9 28 0.9 
16 KALIAMMAL 57 F 62211 92 190 2 6.7 32 0.7 
17 ALAGAR 42 M 59420 121 240 1 7.6 20 1 
18 PALANI 64 M 67599 114 207 1.1 7.1 28 0.9 
19 SIVAKAMI 45 F 59383 114 206 0.9 7.5 18 0.8 
20 SAMIKANNU 70 M 66651 110 210 1 7.3 29 0.9 
21 ANBU 45 M 58114 114 220 0.9 7.4 18 0.9 
22 RAKAYI 53 F 66953 94 176 1.9 6.5 29 0.8 
23 CHELLAPPAN 69 M 65555 124 220 0.9 7.4 30 0.9 
24 MANI 44 M 59114 116 219 0.8 7.5 22 0.8 
25 CHELLAPPAN 50 M 59211 92 190 1.9 6.2 24 0.8 
26 MOHAMMAD 43 M 66818 91 182 1.8 6.3 23 1.1 
27 CHINNAKANNU 46 F 59309 124 204 1.1 7.2 25 0.9 
28 DURAIPANDI 68 M 65656 110 209 0.9 7.5 25 0.8 
29 RAMASAMY 69 M 67515 107 217 1 7.2 26 0.7 
30 SURULAI 65 M 65566 110 212 0.9 7.4 28 0.8 
31 MARIAPPAN 39 M 68104 99 122 2.1 6.5 19 0.7 
32 PALANISAMY 39 M 61414 96 110 0.8 6.5 25 0.8 
33 ALAGAR 64 M 61742 114 232 1 7.5 29 1 
34 KANNAPPAN 68 M 67611 90 184 1 6.2 30 0.9 
35 CHINNASAMY 62 M 66078 92 192 0.9 6.3 29 0.9 
36 NAGARAJ 43 M 59419 114 211 1.1 7.2 20 0.9 
37 PARVATHI 51 F 67391 97 184 1.8 6.6 28 0.9 
38 PALANISAMY 63 M 61182 96 180 1.1 6.1 30 0.7 
39 NALLU 46 M 66214 115 210 1.2 7.1 18 0.9 
40 FATHIMA 54 F 60193 98 171 1 6.4 28 1.1 
41 CHINNADEVAR 64 M 67680 90 192 1.8 6.6 28 0.8 
42 PANDI 65 M 60968 92 190 1.9 6.5 24 0.9 
43 MALLIKA 52 F 63466 96 180 1.6 6.5 24 0.8 
44 VEERANAN 42 M 58314 110 211 1 7.2 22 1 
45 CHAKRAVARTHI 64 M 61977 94 182 1.8 6.5 26 0.9 
46 LAKSHMI 53 F 67390 112 209 0.9 7.4 24 1 
47 MUTHUSAMY  35 M 60414 124 209 0.9 7.4 20 1 
48 MANI 39 M 54318 114 250 1.1 7.6 19 0.8 
49 JANAKI 59 F 60899 116 211 0.9 7.3 27 0.8 
50 PITACHAI 44 M 58240 112 230 1 7.4 24 0.9 
51 MARUTHU 63 M 67622 92 180 2 6.4 28 1 
52 ANJALAI 44 F 59159 99 180 2.1 6.5 24 0.9 
53 MANIKANKAN 64 M 63455 91 180 2.1 6.5 30 0.9 
54 PONNUTHAI 65 F 69154 121 211 1.2 7.5 32 0.8 
55 CHANDRAN 41 M 54110 114 241 1 7.6 22 0.9 
56 KANNATHAL 62 F 67810 96 190 1.1 6.2 28 0.7 
57 PONNUTHAI 45 F 66149 98 172 1.9 6.5 24 1 
58 VALLI 63 F 69213 82 160 1 6.6 24 0.9 
59 SORNALAKSHMI 59 F 63291 114 207 1 7.1 26 0.9 
60 RAVI 50 M 58119 96 168 1.1 6.8 26 0.9 
61 ALAGI 66 F 65188 94 162 2.1 6.5 29 0.8 
62 KALIAMMAL 49 F 59166 84 174 1.8 6.4 22 0.9 
63 CHINNAKANNU 67 F 67911 90 174 1.9 6.1 18 0.7 
64 KANNATHAL 55 F 67311 112 210 1.1 7.2 24 0.8 
65 CHINNAKANNU 45 M 66333 100 188 1.1 6.6 24 1 
66 MOOKAMMAL 50 F 66577 98 176 1 6.5 23 1 
67 BASKARAN 50 M 65144 94 190 1.2 6.3 28 0.8 
68 PANDIDURAI 54 M 61199 93 176 1.5 6.5 25 0.7 
69 PALANI 43 F 65844 94 174 0.9 6.4 24 1.1 
70 MANI 53 M 61114 94 174 1.6 6.6 28 0.8 
71 RAMU 37 M 56008 92 198 1.1 7.5 21 1 
72 PAULSAMY 38 M 71438 120 211 0.9 7.3 24 0.9 
73 ESWARAN 49 M 58746 96 176 1 6.5 22 0.9 
74 PANDIAMMAL 41 F 59911 93 163 1.5 6.4 21 1 
75 KALIAPPAN 56 M 63390 96 180 2 6.5 29 0.9 
76 KASILINGAM 54 M 67292 112 182 1.6 6.5 28 1 
77 SORNAM 42 F 59529 99 182 1 6.7 24 0.9 
78 PALANI 53 M 63311 120 184 1 6.4 29 0.9 
79 GANDHI 46 M 59698 98 174 1 6.5 30 0.8 
80 KANDASAMY 53 M 60333 110 176 1.1 6.5 30 0.8 
81 MASANAM 55 M 61057 94 193 1.8 6.8 18 0.9 
82 PANDI 53 M 60157 106 174 0.9 6.3 29 0.9 
83 LAKSHMANAN 48 M 66414 94 180 1.1 6.4 28 1 
84 VALLI 45 F 65711 92 140 1.1 6.9 27 0.7 
85 ALAGARSAMY 35 M 71111 82 120 1.4 6.1 26 0.8 
86 PARVATHI 42 F 65629 96 176 2 6.3 21 0.8 
87 PANDI 47 M 58818 98 162 1.1 6.3 24 1 
88 VEERANAN 60 M 67201 110 227 1 7.4 25 0.7 
89 MUTHUMARI 52 M 61005 114 200 1.1 6.5 27 0.8 
90 PALANI 49 M 59147 92 188 1.5 6.5 30 0.8 
91 MARUTHU 59 M 60096 116 220 0.9 7.4 27 0.9 
92 MAIDEEN 59 M 60156 110 240 0.9 7.2 28 1 
93 ALAGU 47 M 66800 91 180 1.6 6.7 24 0.9 
94 KARUTHAPPAN  59 M 63201 112 211 1 7.2 25 1 
95 YOGALAKSHMI 49 F 59591 89 156 0.9 6.8 26 0.8 
96 PANDI 33 M 62114 92 124 2 6.3 28 0.9 
97 KURALARASU 37 M 66111 94 110 1.8 6.4 19 0.8 
98 RAGHURAM 48 M 59289 94 170 1.7 6.6 26 0.8 
99 RAJA 48 M 65221 93 164 1.6 6.2 18 0.7 
100 SARASU 43 F 66888 110 204 0.8 7.4 24 0.9 
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1 NARAYANAN 31 M 69111 92 142 2 38 0.9 
2 VELLADURAI 45 M 69141 85 124 1.8 33 1 
3 SATHISH 47 M 70124 93 116 2.2 28 0.9 
4 SIVANESAN 48 M 65655 92 120 2 37 0.8 
5 LAKSHMI 42 F 68433 81 125 2.3 24 0.9 
6 RAMAYEE 50 F 69555 96 124 2 29 0.8 
7 SENBAGARAM 44 M 69161 88 120 1.8 34 1 
8 VEERAPANDI 48 M 70001 96 126 2.1 38 0.8 
9 GANAPATHY 36 M 70199 90 136 2.1 28 1 
10 PERIYAKARUPPAN 44 M 69911 84 127 1.8 30 0.9 
11 VANI 41 F 68444 99 129 1.9 30 0.7 
12 SIVA 41 M 69961 93 122 2.1 30 1 
13 MUTHUKUMAR 53 M 70818 95 124 2 28 0.8 
14 RAMAKRISHNAN 54 M 71600 93 122 1.8 30 0.9 
15 KARMEGAM 32 M 71462 91 140 1.5 24 0.8 
16 MEENAKSHI 44 F 69182 87 123 2.4 28 1 
17 MANI 59 M 70707 96 119 2.2 32 0.7 
18 SHENBAGALINGAM 47 M 69653 86 119 2 33 0.9 
19 ARUMUGAM 48 M 69524 94 120 2 31 0.9 
20 MARANAADU 54 M 71706 92 124 2 32 1 
21 MAAYI 45 M 69143 87 119 2.4 35 0.9 
22 SUNDARAVADIVU 46 F 71432 97 126 1.8 30 0.9 
23 ILAYARAJA 32 M 69948 82 141 2 29 0.8 
24 IYYANAR 54 M 70806 96 121 1.9 24 0.9 
25 VELMURUGAN 58 M 69816 95 124 2.3 29 0.7 
26 GNANAPANDI 55 M 68909 94 122 2.1 30 0.9 
27 SANKARALINGAM 50 M 69151 94 130 1.9 36 0.8 
28 RAVI 55 M 67514 96 124 2 28 1 
29 PAPATHI 55 F 63314 96 121 1.9 34 0.9 
30 RAMAR 46 M 70424 91 120 2 28 1 
31 KRISHNAN 57 M 68814 95 121 2.4 30 0.7 
32 MARUTHALINGAM 46 M 69513 92 129 2.3 34 1 
33 NAATUDURAI 56 M 69514 93 119 1.8 33 1 
34 RANGARAJAN 31 M 69698 98 142 1.6 29 1.1 
35 KATHIRESAN 57 M 68414 92 119 1.7 38 1 
36 VANI 54 F 66844 99 124 1.8 28 1 
37 KRISHNA 49 M 70411 95 124 2 29 0.9 
38 KAALI 56 F 73806 88 119 1.8 30 1 
39 MARUTHAMUTHU 37 M 68924 96 148 2.2 28 1 
40 NATARAJAN 47 M 70015 97 128 2.1 32 1 
41 GOMATHI 45 F 66411 88 128 2.1 29 0.8 
42 VALARMATHI 58 F 73414 98 122 1.8 27 1 
43 KALIMUTHU 43 M 70142 83 125 2.2 29 0.8 
44 KALAIVANI 53 F 73916 82 121 1.7 32 0.7 
45 BAKKIYAM 64 F 71666 89 118 2.1 38 0.9 
46 VALLI 44 F 71163 98 122 1.7 32 0.9 
47 SUBRAMANI 49 M 70086 95 124 1.9 30 1 
48 PARANTHAMAN 46 M 69181 98 120 2 31 1 
49 KALIAMMAL 69 F 72142 89 124 2 38 1 
50 PATCHAIAMMAL 70 F 70809 95 126 1.9 30 0.9 
51 MACHAKAALAI 33 M 70611 93 142 2.1 25 0.8 
52 PAPATHI 59 F 74866 86 119 1.9 34 0.9 
53 PETCHI 65 F 71717 92 124 1.8 34 1 
54 SARASWATHI 47 F 71086 96 124 2.4 22 0.8 
55 PONRAJ 38 M 71423 86 141 2.3 30 0.9 
56 VEERAMMAL 68 F 73866 94 110 1.9 37 1 
57 THANGAVEL 33 M 69121 92 136 1.7 29 0.7 
58 RANGARAJAN 64 M 74711 88 118 2.2 33 0.9 
59 PARVATHI 43 F 70177 92 128 1.8 38 1 
60 RAJU 34 M 70092 94 124 2.2 30 0.8 
61 ARUMUGAM 69 M 71724 95 124 1.9 34 1 
62 PERIANNAN 64 M 70539 89 110 1.8 34 1 
63 RAMALAKSHMI 48 F 73486 83 121 2 26 1 
64 MAHALINGAM 63 M 68333 92 124 2 36 0.9 
65 SREENIVASAN 62 M 69811 92 126 1.9 34 1 
66 RAMU 39 M 71091 88 116 2.4 26 0.9 
67 LATHA 43 F 69146 95 123 2.3 27 0.8 
68 SUBBAIAH 68 M 66196 95 120 1.8 28 0.9 
69 MURUGAVEL 63 M 67320 88 114 1.4 32 0.7 
70 PARASURAM 66 M 66194 92 112 1.3 36 1 
71 KANNAN 34 M 72209 95 151 1.8 28 1 
72 SELVAM 67 M 67279 89 108 1.6 34 1 
73 MANI 35 M 69131 97 132 2.3 31 0.9 
74 MALLIGA 42 F 69999 94 130 2.2 24 0.9 
75 SEKAR 64 M 68978 94 112 1.4 30 0.9 
76 BABULAL 62 M 69455 95 116 1.3 38 0.9 
77 KRISHNAN 40 M 72609 87 126 2.5 27 0.7 
78 THAIYALNAYAGI 49 F 68941 92 123 1.9 28 1 
79 VALLI 36 F 71142 89 122 1.9 32 0.8 
80 KALAI 42 F 66933 88 128 2.1 30 1 
81 MALAISAMY 66 M 74837 94 124 1.4 37 0.9 
82 SUBBURAJ 41 M 69616 91 128 1.6 38 0.9 
83 AIYYAVU 60 M 71446 92 121 2.1 29 0.7 
84 PERUMAL 63 M 71113 92 114 1.8 32 0.9 
85 DHANDAPANI 50 M 69572 98 130 2.3 39 0.8 
86 KARUPAAYEE 41 F 63846 88 121 2 28 0.9 
87 MURUGAN 61 M 70846 95 116 1.9 38 0.7 
88 MUNUSAMY 42 M 69174 89 124 2.1 23 1 
89 MARIAMMAL 60 F 72149 95 122 1.9 34 1 
90 ALAGU 55 M 68913 95 118 2.2 28 0.9 
91 ADAIKAN 43 M 69544 99 120 2.2 32 0.9 
92 KANNATHAL 51 F 72243 91 118 1.7 29 0.9 
93 MARI 49 M 69171 100 118 1.7 35 0.7 
94 MAHALINGAM 51 M 71888 88 121 1.9 30 1 
95 RAJENDRAN 52 M 68841 91 122 1.9 29 0.9 
96 JAYAPAL 53 M 69814 84 124 2 38 0.9 
97 BOSE 43 M 69511 90 121 2.1 32 1 
98 PALANIAMMAL 52 F 73343 90 126 1.8 30 1 
99 RAMALINGAM 51 M 69743 92 119 2.2 30 0.7 
100 SOLAI 42 M 69575 86 119 2 33 1 
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